Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition


TUSTIN, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced that the company will exhibit at the upcoming 2017 BioProcess International Conference & Exhibition, being held September 25-28, 2017 in Boston, MA.  Avid will host a corporate booth (#918) in the conference’s exhibit hall, where it will showcase the company’s comprehensive range of process development, analytical development, testing and characterization services and high quality cGMP clinical and commercial biologics manufacturing of monoclonal antibodies and recombinant proteins. Avid representatives attending the conference will include newly appointed president Roger Lias, Ph.D., and Steven King, who is stepping down from his role as president of Avid, but remaining as president and chief executive officer of Peregrine.  

At BioProcess International, the Avid team will be able to discuss the company’s innovative processes for generating a broad range of biopharmaceutical product types including monoclonal antibodies, highly-glycosylated recombinant proteins and enzymes, among others.  As part of its exhibit, the company will provide a virtual tour of the company’s 42,000 square foot state-of-the-art Myford manufacturing facility, which is designed for late-stage clinical and commercial biologics manufacturing. As previously announced, the company will soon be ready to offer new larger scale capacity from the two recently installed 2,000-liter, single-use bioreactors at the Myford facility. 

The Myford facility is designed with cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process.  A wide range of innovative features are incorporated into this new facility including monolithic modular clean rooms, dedicated support utilities for each key processing area, and the industry’s most advanced single-use production systems and flexible solutions.  Uni-directional process flows separate personnel and materials and provide assurance that the design meets the most stringent regulatory requirements for commercial biologics API manufacturing. 

For more information on the 2017 BioProcess International Conference & Exhibition, please visit: https://lifesciences.knect365.com/bioprocessinternational/.

Avid Bioservices was established as Peregrine’s internal biologics manufacturing and development group, and began formal operations in January 2002.  The company has grown from an internal support operation to a full service CDMO that manufactures bulk drug substance for products that are approved and marketed in over 18 countries by leading biopharma companies, including the US and EU. Avid was recently recognized as a leading CDMO by Life Science Leader as a recipient of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise and Compatibility. The company has an outstanding regulatory inspection history, including 12 years of commercial manufacturing and state-of-the-art cGMP manufacturing facilities. 

About Avid Bioservices, Inc.
Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, including 12 years of commercial manufacturing for products sold in 18 countries, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, lot release and stability testing, regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, qualification/validation, process and product characterization. For more information about Avid, please visit www.avidbio.com.

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products.  Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers.  The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer.  For more information, please visit www.peregrineinc.com.

Contacts:
Kelly Pisarev Lord            
Avid Bioservices, Inc. 
(800) 987-8256  

Stephanie Diaz (Investors)
Vida Strategic Partners 
415-675-7401                    
sdiaz@vidasp.com            

Tim Brons (Media)          
Vida Strategic Partners 
415-675-7402                    
tbrons@vidasp.com           





For further information please contact: